Apexigen will generate and screen antibodies to several targets specified by Centocor R&D, which will be responsible for development and commercialization of all products resulting from the collaboration.
Apexigen will receive an upfront license fee, and is eligible to receive future milestone and royalty payments if certain development and commercialisation milestones are achieved.
Apexigen president & CEO Xiaodong Yang said that they are excited about this collaboration and look forward to working closely with Centocor R&D.